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erate GI adverse events compared to 30.8% patients treated with
racemic ibuprofen.
Conclusions: The results confirmed that dexibuprofen i.e. S(+)-
isomer of ibuprofen in a dose of 1200mg/day was more effica-
cious and better tolerated as compared to ibuprofen 1800 mg/day
and could therefore be a more suitable option in the symptomatic
treatment of patients with osteoarthritis of the knee
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Purpose: We developed of a lateral wedged insole with elastic
strapping of the subtalar joint (the strapped insole) for a treatment
of medial compartment osteoarthritis of the knee (knee OA). In
this presentation, we would like to introduce summaries of our
seven published articles about the strapped insole from 2001 to
2006.
Methods: The subjects were the following: 1) the effect on lower
extremity alignment (J Rheumatol, 2001), 2) the relationship
between participants’ characteristics and efficacy (J Rheumatol
2002), 3) the specific symptomatic efficacy (Arthritis Rheum,
2002), 4) the optimal elevation of wedge (Arch Phys Med Rehabil,
2004), 5) the six month follow-up (Arthritis Rheum, 2004), 6) the
optimal duration of daily wear (Osteoarthritis Cartilage, 2005)
and 7) the two year follow-up (Osteoarthritis Cartilage, 2006).
Results: 1) Participants wearing the strapped insole demon-
strated significantly decreased femorotibial angle and signifi-
cantly improved VAS in comparison with baseline assessments.
2) A significant correlation was observed between lower extrem-
ity lean body mass per body weight and symptomatic relief of
OA of the knee. 3) The efficacy brought about pain reduction
(at night, upon awakening, and on standing from a seated posi-
tion) and increased the maximum distance of ambulation. 4) For
constant routine use, the 12mm elevation wedged insole with
subtalar strapping may be more comfortable and effective than
the 8 or 16mm elevation wedges. 5) The strapped insole main-
tained the valgus correction of the femorotibial angle in patients
with varus knee OA for six months, indicating a longer-term clini-
cal improvement. 6) The remission score of Lequesne index was
significantly improved in the participants treated with a strapped
insole for between five and ten hours each day compared with
that found in the participants treated with the insole for more than
10 hours each day. 7) The strapped insole maintained the valgus
correction of the femorotibial angle in patients with varus knee
OA for two years. If the insole maintains FTA for more than two
Fig. 1. The strapped insole.
years, it may restrict the progression of degenerative articular
cartilage lesions of knee OA.
Conclusions: A conservative therapy such as use of an insole
that provides a low cost, effective compliment or alternative to
surgical treatment would be a very useful adjunct to the care of
these patients and of benefit to the health care economy.
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Purpose: To evaluate the safety and efficacy of hylan G-F 20
viscosupplementation in patients with symptomatic osteoarthritis
(OA) of the shoulder without rotator cuff tear.
Methods: Prospective, multi-center, open study in patients with
gleno-humeral OA (confirmed by X-ray) and no major rotator
cuff tear (confirmed by MRI or arthroscan). At baseline, patients
had to score between 40-90 on the Patient-completed Shoulder
OA Pain VAS (0 - 100 mm). Patients received one intra-articular
injection of 2 ml of hylan G-F 20 and were given an option
of a second and final 2 ml injection if their pain remained
between 40-90 mm on the VAS after 1, 2 or 3 months. Injections
were done under fluoroscopic guidance (maximum of 1 ml of
contrast product). Patients were followed for 6 months after the
final injection. As rescue medication, patients could only take
paracetamol up to 4 g per day, except on the day of or the
day before a study visit.All treatment emergent adverse events
(AEs) were recorded. The primary efficacy endpoint was change
from baseline (at final injection) in the Shoulder OA Pain VAS
at 3 months after the final injection. Secondary endpoints were
Shoulder OA Pain VAS scores at all other time-points, WOOS
scale, Patient’s and Physician’s Global OA assessment (VAS),
and health-related quality of life (SF-36).
Results: Thirty-three patients (18 M; 15 F) were enrolled and
received a first injection of hylan G-F 20. Sixteen patients (48%)
received a second injection. The mean age was 56.7 years
(range 38-80). 85% of patients had idiopathic shoulder OA.
Twenty-nine patients completed the study. Overall, treatment
with hylan G-F 20 was well tolerated. Eight patients (24.2%) had
a treatment related AE of the target shoulder. All were of mild or
moderate intensity, the majority consisting of shoulder pain and
injection site pain. There was a statistically significant decrease
in Shoulder OA Pain VAS score from 61.2 mm at Baseline to 32.5
mm at Month 3 (p<0.001, paired t-test), which was maintained
at 6 months follow-up (32.3 mm). The decrease was statistically
significant at all time points. Patients who received only 1 injection
demonstrated a greater decrease at 3 months (-33.2 mm) than
patients with 2 injections (-18.8 mm). The secondary efficacy
endpoints showed similar results. Of the total study population,
18 patients (60%) were responders (i.e. at least a 50% decrease
in shoulder OA pain) after 3 months. 75% of patients receiving 1
injection were responders after 3 months.
Conclusions: Treatment of OA of the shoulder with intra-articular
hylan G-F 20 injections is well tolerated. Treatment with hylan
G-F 20 significantly decreases pain which is maintained for up to
6 months.
